Robust Drugs Pipeline to Pave Way for Growth in Immunotherapy Drugs Market

Set to grow at a stellar pace over the next few years, the global immunotherapy drugs market is on an upward growth trajectory. Factors such as preference of targeted therapy over traditional therapy and increase in incidence of poor lifestyle related disorders are helping the market grow. Additionally, emergence of biosimilars is also contributing remarkably to the projected growth of the market. It is also worth mentioning here an increase in incidence of chronic illness and rise in demand of monoclonal bodies, factors that are significant in driving the global immunotherapy drugs market.

Get Sample Copy of this Report @

In the United States of America,, which is considered robust in terms of healthcare, the number of people suffering from chronic illnesses is quite grim – six in every ten people in the region are suffering from one chronic illness, two in ten are suffering from more than one.

Some of the top chronic illnesses, the treatment for which is heavily reliant on immunotherapy drugs, are cancer, heart diseases and kidney failure. Lifestyle diseases that are pushing the global immunotherapy drugs market on to a higher and steeper curve include diabetes, depression, hypertension, and obesity. These often need hospitalization for critical care (when aggravated). It is worth noting here that these diseases are witnessing a massive increase in incidence.

Region-wise, North America would be a dominant player in the global immunotherapy. This is attributable to presence of prominent players, extensive research and development activity, and a rapidly ageing population. One in four people in the region will be aged 65 and above by the year of 2050. It is noteworthy though not surprising that the United States is set to contribute immensely to the growth of the market.

Check Table of Contents of this Report @

In the consolidated and moderately competitive vendor landscape of global immunotherapy drugs market, the prominent players include AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

Chronic Diseases, Cancer Cases Driving Growth in Immunotherapy Drugs Market

The global immunotherapy drugs market is set to chart an upward curve over the coming years, owing to a robust CAGR (Compound Annual Growth Rate) predicted. It will create numerous opportunities of growth for market players to take serious note. Besides, the value of the market worth is set to increase over the coming period.

Get Sample Copy of this Report @

This will be driven by a number of factors such as increase in incidence of cancer and other chronic diseases. It is worth noting here that every year, out of 100,000 people (both men and women, 439.2new cases emerge. To understand the magnitude of chronic diseases, a peep into the United States gives gruesome figures. Here, out of every 10 adults, 6 suffer from a chronic disease. And out of every 10, 4 report having more than one chronic diseases. It is worth noting here that the trend will continue in the times to comes, even elsewhere on the globe.

It is also important to note here that rise in infections is also leading to growth in the global immunotherapy drugs market. And, a growing geriatric population is paving the way for further growth, as this demographic is particularly susceptible to such diseases. As per a recent study, one in six people worldwide will fall into the age bracket of geriatrics – 65 and above. Already in 2018, the number of geriatrics surpassed the number of people in the age bracket five and below. Besides, the number of geriatrics will be more pronounced in North America and Europe. The ration of geriatrics to the rest in these regions will be one in four.

Check Table of Contents of this Report @

The global immunotherapy drugs market is consolidated and prominent players in the market landscape include F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc.

Rising Prevalence of Lifestyle Diseases to Boost Immunotherapy Drugs Market

Immunotherapy drugs are mainly used for either suppressing or enhancing the immune system of the body. Such drugs are mainly designed to stimulate body’s immune system to fight against cancer. Immunotherapy drugs help in generating an immune response through producing antibodies.

Cell-based immunotherapies are mainly useful for various types of cancers. Several immune effector cells such as lymphocytes dendritic cells, natural killer cells, cytotoxic T lymphocytes work collectively for protecting the body against different types of cancers. The core function of the cell-based immunotherapy lies in directly attacking the cancer cells through identifying tissue-associated antigens (TAAs). On the other side, passive immunotherapies helps in improving body’s responses in cancer fighting.

Get Sample Copy of this Report @

Apart from the cancer, other common diseases that can be fought off through using immunotherapy include multiple sclerosis, psoriasis, colitis, rheumatoid arthritis, and Crohn’s disease. Such advantages are majorly driving the global immunotherapy drugs market. Immunotherapy drugs helps in generating several types of responses for fighting cancer includes increasing the cancer cells vulnerability, building additional cancer-fighting cells, manipulating the growth rate of cancer cells, and converting malignant cells to normal cells.

Going forward, the global immunotherapy drugs market is gaining traction, owing to the various conveniences it provide to the cancer patients.

Rapid Adoption of Targeted Therapies to Fuel Market’s Growth

Rising prevalence of various lifestyle diseases and rapid adoption of various targeted therapies are majorly boosting the global immunotherapy drugs market. Along with these, increasing demand for expanding life-span of cancer patients and governments’ approvals in launching immunotherapy drugs for reducing the recurrence of diseases are also propelling expansion in the global immunotherapy drugs market.

Read Comprehensive Overview of Report @

Furthermore, immunotherapy is majorly used as an alternative to chemotherapy. Thus, using immunotherapy as the first line of drug for treating various cancers provide wide growth opportunities to the players in the global immunotherapy drugs market.

Immunotherapy Drugs Market – Improvement in body’s current cancer 2025

Global Immunotherapy Drugs Market: Snapshot

Cancer immunotherapy requires the use of a body’s immune system to fight off cancer. The three types of immunotherapies available are passive, active, and hybrid. The core functionality of immunotherapy revolves around the presence of tissue-associated antigens, or TAA’s, which are molecules present on the surface of cancer cells. These are more commonly found as macromolecules such as carbohydrates, or proteins. In the case of active immunotherapy, the immune system is directed to attack cancer cells by identifying TAAs, whereas passive immunotherapies involve the improvement of a body’s current cancer fighting responses. These include the usage of cytokines, lymphocytes, and monoclonal bodies.

Immunotherapy may also be recognized as biological response modifier therapy, or biological therapy. Apart from cancer, the more common types of diseases that can be fought off using immunotherapy are psoriasis, multiple sclerosis, colitis, Crohn’s disease, and rheumatoid arthritis. The principal cause of requiring immunotherapies is the added boost they provide to a body’s immune system to defeat cancer, which the body could not have done otherwise. There are some biological response modifies that a human body can already produce, but the volume may not always be enough to successfully cure cancer, in which case lab produced drugs and treatments come into play. From a simpler perspective, immunotherapies can provide different types of responses within a body to fight cancer. These include building additional cancer-fighting cells, increase the vulnerability of cancer cells, convert cancer cells to normal ones, or manipulate the growth pattern and rate of cancer cells.

Request Sample Copy of the Report @

Global Immunotherapy Drugs Market: Overview

Immunotherapy represents a niche treatment area in the medical industry, which involves a course of treatment that enhances or suppresses the immune system of a patient, making it capable of fighting a number of diseases such as cancer, a number of infections, respiratory conditions. The market for immunotherapy drugs has witnessed expansion at a significant pace in the past few years, chiefly owing to the vast rise in prevalence of chronic diseases and a variety of cancers, and the pressing need for effective drugs with fewer side effects.

The market has also gained traction owing to the increased demand for targeted therapies across the globe and the approval of several immunotherapy drugs in the past few years, making the market more competitive and dynamic. However, certain factors are posing challenges to the growth of the market, including the high cost of immunotherapy drugs, vast capital investment required to initiate research and development processes, and strict drug approval guidelines across some developed regional markets. Nevertheless, vast growth opportunities can be observed for immunotherapy drugs in emerging economies and the field of cancer treatment as an alternative to chemotherapy.

Request TOC of the Report @

Global Immunotherapy Drugs Market: Scope of the Report

This report on the global immunotherapy drugs market provides a detailed qualitative and quantitative analysis of the present and past growth dynamics of the market, including an overview of determining factors such as drivers, challenges, trends, and opportunities. The report also presents an attractiveness analysis of the market and its key segments by criteria such as application, end-use sector, country, and competitive landscape. The competitive landscape section of the report analyzes the level of competition, competitiveness between key players, and market share for some of the key vendors in the market.

Primary research, which forms the bulk of the research efforts undertaken to collate the report, included data sourced from e-mail interactions, personal interviews, and telephonic interviews. Secondary research efforts utilized while creating the report involved the thorough analysis of annual reports, company websites, stock analysis presentations, a number of national and international databases, and press releases. The report provides market size for all key segments across key regional markets in terms of US$ mn/bn over the period between 2017 and 2025, considering several micro- and macro-economic factors influencing the overall growth prospects of the market.

Read Comprehensive Overview of Report @ 

Global Immunotherapy Drugs Market: Segmentation

The report segments the global immunotherapy drugs market on the basis of criteria such as end-user, application, product type, and geography. On the basis of product type, the report examines immunotherapy drug types such as vaccines, monoclonal antibodies, checkpoint inhibitors, and interleukins. On the basis of are of application, the market is segmented into infectious diseases, cancers, and autoimmune diseases. Of these, immunotherapy drugs for the treatment of cancer presently forms the bulk of revenue generated by the market. The significant rise in prevalence of the disease is expected to continue to lead to the demand for an increasing number and varieties of immunotherapy drugs in the next few years as well.

Global Immunotherapy Drugs Market: Geographical and Competitive Landscape

From a geographical perspective, the immunotherapy drugs market has been examined for regions such as North America, Europe, Asia Pacific, and Middle East and Africa. Of these, the market for immunotherapy drugs in North America is presently the leading contributor to the revenue of the global market throughout the report’s forecast period. Asia-Pacific, with its vast pool of geriatric population and an affluent middle class willing to spend on quality healthcare products, is expected to emerge as the most promising investment destination for the immunotherapy drugs market over the report’s forecast period.

Some of the key vendors operating in the global immunotherapy drugs market are Merck & Co., Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb, GlaxoSmithKline, and AbbVie, Inc.